Search Results - "Jongsma, Maria M.E."

Vedolizumab Trough Levels in Children With Anti‐Tumor Necrosis Factor Refractory Inflammatory Bowel Disease by Aardoom, Martine A., Jongsma, Maria M.E., Vries, Annick, Wolthoorn, Jasja, Ridder, Lissy, Escher, Johanna C.

“…ABSTRACT Objectives: Inflammatory bowel disease (IBD) can be successfully treated with vedolizumab. Studies in adult IBD patients have shown that differences…”
Get full text

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial by Jongsma, Maria M E, Aardoom, Martine A, Cozijnsen, Martinus A, van Pieterson, Merel, de Meij, Tim, Groeneweg, Michael, Norbruis, Obbe F, Wolters, Victorien M, van Wering, Herbert M, Hojsak, Iva, Kolho, Kaija-Leena, Hummel, Thalia, Stapelbroek, Janneke, van der Feen, Cathelijne, van Rheenen, Patrick F, van Wijk, Michiel P, Teklenburg-Roord, Sarah T A, Schreurs, Marco W J, Rizopoulos, Dimitris, Doukas, Michail, Escher, Johanna C, Samsom, Janneke N, de Ridder, Lissy

“…In newly diagnosed paediatric patients with moderate-to-severe Crohn's disease (CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN),…”
Get more information

Infliximab in young paediatric IBD patients: it is all about the dosing by Jongsma, Maria M. E., Winter, Dwight A., Huynh, Hien Q., Norsa, Lorenzo, Hussey, Seamus, Kolho, Kaija-Leena, Bronsky, Jiri, Assa, Amit, Cohen, Shlomi, Lev-Tzion, Raffi, Van Biervliet, Stephanie, Rizopoulos, Dimitris, de Meij, Tim G. J., Shouval, Dror S., Wine, Eytan, Wolters, Victorien M., Martinez-Vinson, Christine, de Ridder, Lissy

“…Infliximab (IFX) is administered intravenously using weight-based dosing (5 mg/kg) in inflammatory bowel disease (IBD) patients. Our hypothesis is that…”
Get full text

Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn’s Disease by Cozijnsen, Martinus A., Ben Shoham, Assaf, Kang, Ben, Choe, Byung-Ho, Choe, Yon Ho, Jongsma, Maria M.E., Russell, Richard K., Ruemmele, Frank M., Escher, Johanna C., de Ridder, Lissy, Koletzko, Sibylle, Martín-de-Carpi, Javier, Hyams, Jeffrey, Walters, Thomas, Griffiths, Anne, Turner, Dan

“…Mucosal healing (MH) has become a goal of therapy for Crohn’s disease (CD), but frequent endoscopies are not feasible. We aimed to develop and validate a…”
Get full text

Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments by Jongsma, Maria M E, Costes, Lea M M, Tindemans, Irma, Cozijnsen, Martinus A, Raatgreep, Rolien (H) C, van Pieterson, Merel, Li, Yunlei, Escher, Johanna C, de Ridder, Lissy, Samsom, Janneke N

“…Abstract Background Despite its efficacy, rational guidance for starting/stopping first-line biologic treatment in individual paediatric Crohn’s disease [CD]…”
Get full text

Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease by Vuijk, Stephanie A., Jongsma, Maria M. E., Hoeven, Britt M., Cozijnsen, Maarten A., Pieterson, Merel, Meij, Tim G. J., Norbruis, Obbe F., Groeneweg, Michael, Wolters, Victorien M., Wering, Herbert, Hummel, Thalia, Stapelbroek, Janneke, Feen, Cathelijne, Rheenen, Patrick F., Wijk, Michiel P., Teklenburg, Sarah, Rizopoulos, Dimitris, Poley, Marten J., Escher, Johanna C., Ridder, Lissy

“…Summary Background Data on cost‐effectiveness of first‐line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are…”
Get full text

Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients by Zijlstra, Marieke, Jongsma, Maria M.E., Vries, Annick, Schaap, Tiny, Bloem, Karien, Ridder, Lissy

“…ABSTRACT Objectives: Blood to measure infliximab (IFX) levels is typically obtained with venipuncture. Dried blood sampling (DBS), using capillary blood…”
Get full text

Combined plasma protein and memory T cell profiling discern IBD-patient-immunotypes related to intestinal disease and treatment outcomes by Heredia, Maud, Charrout, Mohammed, Klomberg, Renz C.W., Aardoom, Martine A., Jongsma, Maria M.E., Kemos, Polychronis, Hulleman-van Haaften, Danielle H., Tuk, Bastiaan, van Berkel, Lisette A., Bley Folly, Brenda, Calado, Beatriz, Nugteren, Sandrine, Simons-Oosterhuis, Ytje, Doukas, Michail, Sanders, Mathijs A., van Beek, Gregory, Ruemmele, Frank M., Croft, Nicholas M., Mahfouz, Ahmed, Reinders, Marcel J.T., Escher, Johanna C., de Ridder, Lissy, Samsom, Janneke N.

“…Inflammatory bowel disease (IBD) chronicity results from memory T helper cell (Tmem) reactivation. Identifying patient-specific immunotypes is crucial for…”
Get full text